Tango TherapeuticsTNGX
TNGX
About: Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Employees: 155
0
Funds holding %
of 7,359 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
63% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 27
43% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 28
13% more funds holding
Funds holding: 121 [Q3] → 137 (+16) [Q4]
4.34% more ownership
Funds ownership: 94.75% [Q3] → 99.09% (+4.34%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]
58% less capital invested
Capital invested by funds: $782M [Q3] → $329M (-$452M) [Q4]
71% less call options, than puts
Call options by funds: $4K | Put options by funds: $14K
Research analyst outlook
We haven’t received any recent analyst ratings for TNGX.
Financial journalist opinion
Negative
Zacks Investment Research
1 week ago
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.32 per share a year ago.
Neutral
GlobeNewsWire
1 week ago
Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights
– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA. Phase 1/2 enrollment expected to begin 1H 2025 – – Clinical collaboration with Eli Lilly to evaluate TNG456 in combination with CDK4/6 inhibitor Verzenio ® (abemaciclib) established – – Data update from ongoing TNG462 monotherapy trial expected in 2025 with focus on pancreatic and lung cancer – – Cash position of $258 million as of December 31, 2024, with cash runway expected to fund operations into 3Q 2026 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported financial results for the fourth quarter and full year ended December 31, 2024, and provided business highlights.
Neutral
GlobeNewsWire
1 month ago
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on Wednesday, February 5, 2025 at 10:00 AM ET.
Positive
Seeking Alpha
1 month ago
Tango Therapeutics: Chance For A Short Squeeze
Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Given the high short interest and the low number of shares outstanding, I expect a short squeeze to occur, which could lead to an increase in TNGX's share price thereafter. Despite the negative sentiment, recent institutional selling and call option activity suggest potential value accumulation and positive momentum for TNGX.
Neutral
Business Wire
3 months ago
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective December 2, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 187,500 shares of its common stock and 31,250 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement.
Neutral
Business Wire
3 months ago
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Adam Crystal, M.D., Ph.D., President, Research & Development of Tango Therapeutics, is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 1:30 PM ET. A live webcast of the presentation will be available under the "Events.
Negative
Zacks Investment Research
3 months ago
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago.
Neutral
Business Wire
3 months ago
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the third quarter ended September 30, 2024, and provided business highlights. “We have made great progress with our PRMT5 development program, including positive data from the TNG462 phase 1/2 clinical trial that showcase the best-in-class potential of TNG462 in multi.
Neutral
Business Wire
3 months ago
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced an update on its PRMT5 program. Based on positive data from the dose escalation and early dose expansion cohorts of the TNG462 phase 1/2 clinical trial, the Company has selected TNG462 to move forward into full development. TNG908, an MTA-cooperative brain penetrant PRMT5 inhibitor, is clinic.
Negative
Seeking Alpha
5 months ago
Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data
Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's clinical results. Tango's financial stability is supported by >$300M in cash, a Gilead partnership, and a funding runway until 2027, covering key clinical readouts.
Charts implemented using Lightweight Charts™